Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
University of Chicago
Case Comprehensive Cancer Center
University of Nebraska
Samus Therapeutics, Inc.
Medigene AG
Novartis
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
University of California, San Francisco
Roswell Park Cancer Institute
M.D. Anderson Cancer Center